Why the study?
To understand the historical and pharmacological process that led neprilysin inhibition to become a pillar of heart failure treatment.
This review summarizes the historical and pharmacological development of neprilysin inhibitors as a foundational pillar of therapy for heart failure with reduced ejection fraction.
Answers are grounded in this paper and cite their sources.
Supports ARNI as first-line HFrEF therapy; reinforces neprilysin inhibition as foundational pillar.
The recognition that alterations in the regulation of the neurohormonal axis are the main factor behind the development and progression of heart failure was fundamental to constructing the pillars of therapy currently available for the treatment of this syndrome. The main objective of this review is to understand the entire historical and pharmacological process that has led neprilysin inhibition to become one of the pillars of heart failure treatment. For years, there was a gap in drug therapy for heart failure with reduced ejection fraction, and it took years to understand neprilysin inhibition, establish its safety, and confirm its effects, in order to achieve the beneficial results we have today.
No takes yet. Share an insight, caveat, or question.
Souza et al. (2024) conducted a review in Heart Failure. Sacubitril-valsartan (Angiotensin Receptor-Neprilysin Inhibitor) vs. Enalapril or Valsartan was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: